Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
PTCT [NASD]
PTC Therapeutics, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-6.87 Insider Own0.60% Shs Outstand67.64M Perf Week-6.20%
Market Cap3.82B Forward P/E- EPS next Y-4.65 Insider Trans-75.66% Shs Float66.17M Perf Month-9.79%
Income-441.50M PEG- EPS next Q-0.94 Inst Own- Short Float6.07% Perf Quarter-11.33%
Sales358.40M P/S10.65 EPS this Y-55.40% Inst Trans1.13% Short Ratio7.79 Perf Half Y10.36%
Book/sh7.55 P/B7.31 EPS next Y28.50% ROA-25.90% Target Price66.50 Perf Year1.56%
Cash/sh16.51 P/C3.34 EPS next 5Y-9.51% ROE-80.00% 52W Range30.79 - 70.82 Perf YTD-9.57%
Dividend- P/FCF- EPS past 5Y-7.50% ROI-27.80% 52W High-22.07% Beta0.97
Dividend %- Quick Ratio4.80 Sales past 5Y64.80% Gross Margin95.10% 52W Low79.23% ATR2.76
Employees754 Current Ratio4.90 Sales Q/Q65.80% Oper. Margin- RSI (14)31.10 Volatility4.75% 4.92%
OptionableYes Debt/Eq1.94 EPS Q/Q3.00% Profit Margin- Rel Volume1.00 Prev Close57.63
ShortableYes LT Debt/Eq1.89 EarningsFeb 25 AMC Payout- Avg Volume515.53K Price55.19
Recom2.30 SMA20-8.06% SMA50-12.48% SMA2000.62% Volume515,504 Change-4.23%
Feb-12-21Downgrade BofA Securities Buy → Neutral
Jan-05-21Upgrade Citigroup Neutral → Buy $67 → $85
Nov-30-20Downgrade RBC Capital Mkts Sector Perform → Underperform $45
Oct-30-20Downgrade Citigroup Buy → Neutral
Oct-28-20Initiated UBS Neutral $55
Oct-07-20Upgrade JP Morgan Neutral → Overweight $71
Aug-25-20Initiated Raymond James Outperform $63
Apr-09-20Upgrade Citigroup Neutral → Buy $71 → $67
Feb-20-20Downgrade RBC Capital Mkts Outperform → Sector Perform
Feb-20-20Downgrade Citigroup Buy → Neutral $55 → $71
Nov-12-19Initiated SunTrust Buy $78
May-13-19Upgrade BofA/Merrill Neutral → Buy $43 → $49
Apr-11-19Initiated Bernstein Outperform $48
Oct-03-18Upgrade BofA/Merrill Underperform → Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $66
Jul-19-18Initiated Credit Suisse Outperform $49
Jun-18-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Apr-04-18Downgrade Barclays Equal Weight → Underweight $24 → $26
Jan-29-18Resumed RBC Capital Mkts Sector Perform
Nov-16-17Upgrade JP Morgan Underweight → Neutral
Feb-25-21 02:30PM  
PTC Therapeutics, Inc. to Host Earnings Call
ACCESSWIRE
Feb-24-21 05:08PM  
Positive Data from FIREFISH Study of Evrysdi (risdiplam) in Infants with Type 1 Spinal Muscular Atrophy Published in The New England Journal of Medicine
PR Newswire
Feb-17-21 08:00AM  
PTC Therapeutics Reports the Initiation of the Second Stage of the FITE19 Phase 2/3 Clinical Trial Evaluating PTC299 for the Treatment of COVID-19
PR Newswire
Feb-16-21 08:00AM  
PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences
PR Newswire
Feb-15-21 04:09AM  
Loss-Making PTC Therapeutics, Inc. (NASDAQ:PTCT) Expected To Breakeven In The Medium-Term
Simply Wall St.
Feb-11-21 08:00AM  
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results
PR Newswire
Feb-04-21 04:01PM  
PTC Therapeutics to Host Call to Review Results from its Study of Translarna (ataluren) in Patients with Nonsense Mutation Duchenne Muscular Dystrophy
PR Newswire
Jan-14-21 08:00AM  
PTC Therapeutics Opens Applications for the Annual STRIVE Awards Program and Introduces a New Award Category
PR Newswire
Jan-13-21 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Jan-11-21 06:30AM  
PTC Therapeutics Provides Update on R&D Pipeline and Commercial Progress at 39th Annual J.P. Morgan Healthcare Conference
PR Newswire
Jan-04-21 08:00AM  
PTC Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
PR Newswire
Dec-31-20 02:57AM  
Can You Imagine How Jubilant Therapeutics' (NASDAQ:PTCT) Shareholders Feel About Its 239% Share Price Gain?
Simply Wall St.
Dec-18-20 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Dec-09-20 08:00AM  
PTC Therapeutics to Host Translarna Deep Dive Webinar
PR Newswire
Dec-04-20 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
08:00AM  
PTC Announces Translarna Approval in Russia for the Treatment of Duchenne Muscular Dystrophy
PR Newswire
Nov-30-20 08:00AM  
PTC Therapeutics Announces Initiation of Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich Ataxia
PR Newswire
Nov-25-20 03:01AM  
Here's What We Think About Therapeutics' (NASDAQ:PTCT) CEO Pay
Simply Wall St.
Nov-19-20 08:00AM  
PTC Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference
PR Newswire
Nov-18-20 08:00AM  
PTC Therapeutics Announces Key Regulatory Designations for PTC596 to Advance Treatment of Two Rare Oncology Indications
PR Newswire
Nov-17-20 08:00AM  
PTC Therapeutics Announces that PTC518 Has Entered into a Phase 1 Clinical Trial for the Huntington's Disease Program
PR Newswire
Nov-16-20 08:00AM  
PTC Therapeutics Highlights Data on High Disease Burden and Value of Treatment Across Two Rare Diseases
PR Newswire
Oct-29-20 05:35PM  
PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates
Zacks
04:01PM  
PTC Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
PR Newswire
02:30PM  
PTC Therapeutics, Inc.to Host Earnings Call
ACCESSWIRE
Oct-28-20 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
08:00AM  
PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences
PR Newswire
Oct-26-20 08:00AM  
PTC Therapeutics Announces Initiation of a Registration-Directed Clinical Trial to Evaluate Vatiquinone in Mitochondrial Epilepsy
PR Newswire
Oct-22-20 12:34PM  
Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for
Zacks
08:00AM  
PTC Therapeutics and AADC Family Network Announce First-Ever AADC Deficiency Awareness Day in Massachusetts
PR Newswire
Oct-21-20 08:33AM  
Evrysdi (risdiplam) Continues to Make Global Progress for the Treatment of Spinal Muscular Atrophy
PR Newswire
Oct-20-20 12:58PM  
Is Therapeutics (NASDAQ:PTCT) Using Debt In A Risky Way?
Simply Wall St.
Oct-15-20 08:00AM  
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2020 Financial Results
PR Newswire
Sep-28-20 01:00AM  
Two-Year Data of Evrysdi (risdiplam) in Infants with Spinal Muscular Atrophy Demonstrate Continued Improvement of Developmental Milestones
PR Newswire
Sep-25-20 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Sep-24-20 08:00AM  
PTC Therapeutics to Present at the Jefferies Virtual Gene Therapy/Editing Summit
PR Newswire
Sep-15-20 11:02AM  
Hedge Funds Are Dipping Their Toes Back Into PTC Therapeutics, Inc. (PTCT)
Insider Monkey
Sep-14-20 03:20PM  
Should You Take Comfort From Insider Transactions At PTC Therapeutics, Inc. (NASDAQ:PTCT)?
Simply Wall St. +6.84%
Sep-09-20 08:00AM  
PTC Therapeutics Launches PTC PINPOINT - A Genetic Testing Program for Individuals Suspected of Having Neurotransmitter Disorders
PR Newswire
Sep-08-20 08:00AM  
PTC Therapeutics' 2020 STRIVE Awards for Duchenne Muscular Dystrophy Recognize Four Patient Advocacy Organizations
PR Newswire
Sep-03-20 08:00AM  
PTC Therapeutics to Present at the Cantor Virtual Global Healthcare Conference
PR Newswire
Aug-27-20 09:39AM  
PTC Therapeutics Gets First Milestone Payment for SMA Drug
Zacks
Aug-26-20 09:44AM  
PTC reports first milestone payment from Roche for spinal muscular atrophy drug
MarketWatch
08:00AM  
PTC Therapeutics Announces First Commercial Milestone Payment Following U.S. FDA Approval of Evrysdi (risdiplam)
PR Newswire
Aug-21-20 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Aug-18-20 05:07PM  
PTC Therapeutics' Application for SMA Drug Accepted by EU
Zacks
Aug-17-20 08:00AM  
PTC Announces the Acceptance of the European Marketing Authorization Application for Evrysdi (risdiplam) for the Treatment of Spinal Muscular Atrophy
PR Newswire
Aug-10-20 07:07AM  
PTC Therapeutics Scores Early FDA Nod For Evrysdi; Analyst Stays Sidelined
SmarterAnalyst
Aug-08-20 10:40AM  
FDA approves Roche's new spinal muscular atrophy drug
MarketWatch
Aug-07-20 02:46PM  
PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Path To Profitability
Simply Wall St.
01:54PM  
PTC Therapeutics Announces FDA Approval of Evrysdi (risdiplam) for the Treatment of Spinal Muscular Atrophy in Adults and Children 2 months and older
PR Newswire
Aug-06-20 08:00AM  
PTC Therapeutics' Mary Frances Harmon Named One of the Most Inspiring Leaders in Life Sciences by PharmaVOICE Magazine
PR Newswire
Aug-05-20 06:15PM  
PTC Therapeutics (PTCT) Reports Q2 Loss, Lags Revenue Estimates
Zacks
04:01PM  
PTC Therapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate Update
PR Newswire
Jul-29-20 12:33PM  
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Should You Buy?
Zacks
Jul-22-20 08:00AM  
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2020 Financial Results
PR Newswire
Jul-21-20 09:00AM  
PTC Therapeutics to Host Deep Dive Webinar on Splicing Platform
PR Newswire -9.70%
Jul-20-20 07:45AM  
Royalty Pharma Acquires Royalty Interest in Risdiplam From PTC Therapeutics
GlobeNewswire
07:30AM  
PTC Therapeutics Announces Agreement to Monetize a Portion of the Risdiplam Royalty Stream for $650 Million
PR Newswire
Jul-12-20 08:14PM  
Did Hedge Funds Make The Right Call On PTC Therapeutics, Inc. (PTCT) ?
Insider Monkey
Jul-08-20 08:00AM  
PTC Therapeutics Announces First Patient Dosed in Phase 1 Trial for PTC857
PR Newswire
Jun-29-20 02:04PM  
Edited Transcript of PTCT.OQ earnings conference call or presentation 30-Apr-20 8:30pm GMT
Thomson Reuters StreetEvents
08:00AM  
PTC Therapeutics Announces CHMP Recommendation of Translarna (ataluren) Label Update for Non-Ambulatory Patients with Duchenne Muscular Dystrophy
PR Newswire
Jun-23-20 04:05PM  
Sarepta Addressing Gene Therapy Issue With Two Acquisitions
GuruFocus.com
Jun-18-20 05:53PM  
PTC Announcement on Covid-19 Candidate Met With Investor Indifference
GuruFocus.com
10:25AM  
PTC Therapeutics to Commence Phase II/III Coronavirus Study in US
Zacks
10:16AM  
PTC Therapeutics Initiates Phase II/III Study for Coronavirus
Zacks
Jun-17-20 07:30AM  
The Daily Biotech Pulse: Patent Win For Amarin, FDA Nod For Novartis & Merck, Chembio's Coronavirus EUA Revoked
Benzinga
06:30AM  
PTC Therapeutics Announces the Initiation of a Phase 2/3 Clinical Trial to Evaluate PTC299 for the Treatment of COVID-19
PR Newswire
Jun-12-20 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
04:15PM  
PTC Therapeutics Announces 2-year Data from Part 1 of SUNFISH and New Data from JEWELFISH Trials for Risdiplam in Patients with Spinal Muscular Atrophy
PR Newswire
Jun-10-20 08:00AM  
PTC Therapeutics Launches New "Talent Pipeline Program" to Help Students who Graduated During the 2020 COVID-19 Pandemic
PR Newswire
Jun-08-20 02:47AM  
Hedge Funds Are Selling PTC Therapeutics, Inc. (PTCT)
Insider Monkey
Jun-01-20 08:00AM  
PTC Therapeutics Successfully Completes Acquisition of Censa Pharmaceuticals
PR Newswire
May-28-20 09:00AM  
PTC Therapeutics to Host First Deep Dive Webinar on Bio-e Platform
PR Newswire
May-27-20 07:04PM  
PTC Therapeutics, Inc. to Hold Virtual 2020 Annual Meeting of Stockholders
PR Newswire
May-26-20 08:00AM  
PTC Therapeutics to Present at the Jefferies Virtual Healthcare Conference
PR Newswire
May-21-20 04:27PM  
PTC Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating
Investor's Business Daily
May-15-20 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire +6.15%
May-06-20 04:30PM  
PTC Therapeutics to Acquire Censa Pharmaceuticals
PR Newswire
May-05-20 08:00AM  
PTC Therapeutics to Participate at Upcoming Investor Conferences
PR Newswire
Apr-30-20 06:35PM  
PTC Therapeutics (PTCT) Reports Q1 Loss, Lags Revenue Estimates
Zacks
Apr-28-20 01:00AM  
Confirmatory Part 2 of FIREFISH Demonstrates Survival and Motor Milestones Not Seen in Natural History in Infants with Type 1 Spinal Muscular Atrophy
PR Newswire
Apr-23-20 12:32PM  
Earnings Preview: PTC Therapeutics (PTCT) Q1 Earnings Expected to Decline
Zacks
Apr-22-20 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Apr-17-20 08:00AM  
PTC Therapeutics Announces New Leadership Appointments
PR Newswire
Apr-16-20 08:00AM  
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2020 Financial Results
PR Newswire
Apr-09-20 10:16AM  
Does Therapeutics (NASDAQ:PTCT) Have A Healthy Balance Sheet?
Simply Wall St.
Apr-07-20 04:05PM  
PTC Announces Regulatory Update on Risdiplam for Spinal Muscular Atrophy (SMA)
PR Newswire
Mar-30-20 06:06PM  
FDA Decisions on 5 Drugs Expected in 2nd Quarter
GuruFocus.com +5.45%
Mar-29-20 12:32PM  
Do Hedge Funds Love PTC Therapeutics, Inc. (PTCT)?
Insider Monkey
Mar-25-20 09:04AM  
Edited Transcript of PTCT earnings conference call or presentation 2-Mar-20 9:30pm GMT
Thomson Reuters StreetEvents
Mar-16-20 08:00AM  
PTC Therapeutics Announces Management Change
PR Newswire -26.33%
Mar-11-20 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire -8.32%
Mar-10-20 11:53AM  
The Surprising Impact Coronavirus Will Have On Biotech Companies
Investor's Business Daily
Mar-04-20 09:40AM  
Earnings Update: PTC Therapeutics, Inc. Just Reported And Analysts Are Trimming Their Forecasts
Simply Wall St. +9.33%
Mar-02-20 05:25PM  
PTC Therapeutics (PTCT) Reports Q4 Loss, Tops Revenue Estimates
Zacks
04:01PM  
PTC Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides a Corporate Update
PR Newswire
Feb-25-20 04:30PM  
PTC Therapeutics to Participate at Upcoming Investor Conferences
PR Newswire
Feb-24-20 12:30PM  
Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for
Zacks
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Utter Christine MarieSVP, Finance & CAOFeb 08Option Exercise33.022,65787,73419,166Feb 10 04:24 PM
Utter Christine MarieSVP, Finance & CAOFeb 08Sale66.002,657175,36216,509Feb 10 04:24 PM
Utter Christine MarieSVP, Finance & CAOFeb 02Sale57.6465237,58116,509Feb 03 07:46 AM
Utter Christine MarieSVP, Finance & CAOFeb 01Sale56.9636820,96017,161Feb 03 07:46 AM
Hill Emily LuisaChief Financial OfficerFeb 01Sale56.9654130,81323,306Feb 02 06:24 PM
Boulding Mark ElliottExec. VP and CLOFeb 01Sale56.9677844,31248,374Feb 02 06:23 PM
Almstead Neil GregoryChief Technical Ops OfficerFeb 01Sale56.96281,5951,819Feb 02 06:22 PM
Almstead Neil GregoryChief Technical Ops OfficerFeb 01Sale56.9697355,41835,814Feb 02 06:22 PM
Pauwels EricChief Business OfficerFeb 01Sale56.9636220,61836,487Feb 02 06:21 PM
Peltz Stuart WalterChief Executive OfficerFeb 01Sale56.9628316,11915,081Feb 02 06:19 PM
Peltz Stuart WalterChief Executive OfficerFeb 01Sale56.961,968112,08980,315Feb 02 06:19 PM
Svoronos DawnDirectorFeb 01Sale56.9650628,82027,430Feb 02 06:18 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 25Sale63.1554134,1661,847Jan 27 04:26 PM
Hill Emily LuisaChief Financial OfficerJan 25Sale62.0527517,06523,847Jan 27 04:25 PM
Pauwels EricChief Business OfficerJan 25Sale62.0543126,74536,849Jan 27 04:24 PM
Peltz Stuart WalterChief Executive OfficerJan 25Sale62.0535021,71915,364Jan 27 04:23 PM
Klein Matthew B.Chief Development OfficerJan 15Option Exercise38.984,300167,61423,609Jan 20 04:10 PM
Klein Matthew B.Chief Development OfficerJan 15Sale69.094,300297,07819,309Jan 20 04:10 PM
Utter Christine MarieSVP, Finance & CAOJan 13Option Exercise16.393,28853,87420,029Jan 15 04:04 PM
Utter Christine MarieSVP, Finance & CAOJan 13Sale66.573,947262,75217,529Jan 15 04:04 PM
Hill Emily LuisaChief Financial OfficerJan 08Option Exercise23.5626,033613,40934,622Jan 12 04:15 PM
Klein Matthew B.Chief Development OfficerJan 08Option Exercise38.985,500214,39024,809Jan 12 04:17 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 08Option Exercise27.051,30035,1653,688Jan 12 04:18 PM
Klein Matthew B.Chief Development OfficerJan 08Sale69.715,500383,41019,309Jan 12 04:17 PM
Hill Emily LuisaChief Financial OfficerJan 08Sale69.7526,0331,815,80224,122Jan 12 04:15 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 08Sale69.001,30089,7002,388Jan 12 04:18 PM
Klein Matthew B.Chief Development OfficerJan 07Option Exercise38.983,886151,47623,195Jan 08 05:12 PM
Klein Matthew B.Chief Development OfficerJan 07Sale68.983,886268,05619,309Jan 08 05:12 PM
Boulding Mark ElliottExec. VP and CLOJan 05Sale62.3777248,15038,952Jan 07 05:05 PM
Hill Emily LuisaChief Financial OfficerJan 05Sale62.3728817,96313,322Jan 07 05:02 PM
Pauwels EricChief Business OfficerJan 05Sale62.371,06766,54927,080Jan 07 04:59 PM
Peltz Stuart WalterChief Executive OfficerJan 05Sale62.3766641,53811,754Jan 07 04:57 PM
Peltz Stuart WalterChief Executive OfficerJan 05Sale62.371,40287,44354,683Jan 07 04:57 PM
Utter Christine MarieSVP, Finance & CAOJan 05Sale62.3731619,7099,488Jan 07 04:55 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 05Sale62.371247,7341,788Jan 07 04:54 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 05Sale62.3750231,31026,587Jan 07 04:54 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 04Option Exercise10.856006,5102,512Jan 06 04:06 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 04Option Exercise20.79103,4382,150,35975,214Jan 06 04:06 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 04Sale60.6560036,3901,912Jan 06 04:06 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 04Sale60.58103,4386,266,16727,089Jan 06 04:06 PM
Peltz Stuart WalterChief Executive OfficerDec 30Option Exercise31.74285,7189,067,681225,866Dec 31 04:06 PM
Peltz Stuart WalterChief Executive OfficerDec 30Sale61.74285,71817,641,45956,085Dec 31 04:06 PM
Reeve EmmaDirectorDec 15Option Exercise33.021,02833,9452,678Dec 16 04:09 PM
Reeve EmmaDirectorDec 14Option Exercise33.021,97265,1152,650Dec 16 04:09 PM
Reeve EmmaDirectorDec 14Sale68.001,972134,0961,650Dec 16 04:09 PM
Okey StephanieDirectorDec 08Sale62.5268742,954963Dec 10 04:09 PM
Peltz Stuart WalterChief Executive OfficerDec 07Option Exercise22.66348,4177,894,942248,877Dec 09 07:54 PM
Peltz Stuart WalterChief Executive OfficerDec 07Option Exercise16.6820,017333,95463,675Dec 09 07:52 PM
Peltz Stuart WalterChief Executive OfficerDec 07Sale61.00348,41721,254,76656,085Dec 09 07:54 PM
Peltz Stuart WalterChief Executive OfficerDec 07Sale61.4220,0171,229,48456,085Dec 09 07:52 PM
Almstead Neil GregoryChief Technical Ops OfficerNov 04Option Exercise11.2324,062270,21648,964Nov 06 04:27 PM
Jacobson Allan StevenDirectorNov 04Option Exercise10.8520,000217,00023,498Nov 06 04:30 PM
Utter Christine MarieSVP, Finance & CAONov 04Option Exercise30.9731,758983,52620,187Nov 06 04:35 PM
Peltz Stuart WalterChief Executive OfficerNov 04Option Exercise25.3838,328972,95520,599Nov 06 04:40 PM
Utter Christine MarieSVP, Finance & CAONov 04Sale60.0631,7581,907,4049,562Nov 06 04:35 PM
Jacobson Allan StevenDirectorNov 04Sale60.0020,0001,200,0003,498Nov 06 04:30 PM
Peltz Stuart WalterChief Executive OfficerNov 04Sale60.0049,3652,961,90012,178Nov 06 04:40 PM
Almstead Neil GregoryChief Technical Ops OfficerNov 04Sale60.0024,0621,443,72027,089Nov 06 04:27 PM
Pauwels EricChief Business OfficerNov 03Sale56.506,194349,96127,647Nov 05 04:25 PM
Peltz Stuart WalterChief Executive OfficerNov 02Option Exercise10.8550,000542,500106,085Nov 03 07:52 PM
Peltz Stuart WalterChief Executive OfficerNov 02Sale53.6650,0002,682,95456,085Nov 03 07:52 PM
SOUTHWELL DAVID PDirectorOct 16Option Exercise11.0227,000297,51016,650Oct 20 04:34 PM
Jacobson Allan StevenDirectorOct 16Sale51.295,000256,4503,498Oct 20 04:35 PM
SOUTHWELL DAVID PDirectorOct 16Sale51.5427,0001,391,5441,650Oct 20 04:34 PM
Peltz Stuart WalterChief Executive OfficerOct 07Option Exercise11.1171,104789,785104,260Oct 09 04:20 PM
Peltz Stuart WalterChief Executive OfficerOct 07Sale53.3871,1043,795,26256,085Oct 09 04:20 PM
Peltz Stuart WalterChief Executive OfficerOct 06Option Exercise11.01124,3511,368,902107,910Oct 07 09:01 PM
Utter Christine MarieSVP, Finance & CAOOct 06Option Exercise18.012,50045,02512,062Oct 07 08:59 PM
Utter Christine MarieSVP, Finance & CAOOct 06Sale50.082,500125,2089,562Oct 07 08:59 PM
Peltz Stuart WalterChief Executive OfficerOct 06Sale50.12124,3516,233,08356,085Oct 07 09:01 PM
Utter Christine MarieSVP, Finance & CAOOct 05Option Exercise11.237878,83810,349Oct 07 08:59 PM
Peltz Stuart WalterChief Executive OfficerOct 05Option Exercise10.8555,460601,741110,645Oct 07 09:01 PM
Peltz Stuart WalterChief Executive OfficerOct 05Sale50.0055,4602,773,00056,085Oct 07 09:01 PM
Utter Christine MarieSVP, Finance & CAOOct 05Sale48.6878738,3119,562Oct 07 08:59 PM
Peltz Stuart WalterChief Executive OfficerJul 15Option Exercise10.85100,0001,085,000106,085Jul 17 04:30 PM
Peltz Stuart WalterChief Executive OfficerJul 15Sale55.70100,0005,570,15156,085Jul 17 04:30 PM
Boulding Mark ElliottExec. VP and CLOJul 07Option Exercise15.1030,625462,56957,224Jul 09 04:08 PM
Boulding Mark ElliottExec. VP and CLOJul 07Sale55.1230,6251,688,03739,724Jul 09 04:08 PM
Utter Christine MarieSVP, Finance & CAOJul 06Option Exercise16.393,28853,87412,062Jul 08 04:04 PM
Utter Christine MarieSVP, Finance & CAOJul 06Sale53.703,288176,5649,562Jul 08 04:04 PM
Hill Emily LuisaChief Financial OfficerJun 29Sale52.502,581135,50313,610Jul 01 04:06 PM
Svoronos DawnDirectorJun 11Sale48.3636417,60326,286Jun 12 04:04 PM
Peltz Stuart WalterChief Executive OfficerMay 20Option Exercise10.8533,788366,60089,873May 22 04:05 PM
Peltz Stuart WalterChief Executive OfficerMay 20Sale50.0033,7881,689,40056,085May 22 04:05 PM
Peltz Stuart WalterChief Executive OfficerMay 18Option Exercise10.856,28468,18162,369May 20 04:07 PM
Peltz Stuart WalterChief Executive OfficerMay 18Sale50.126,284314,97956,085May 20 04:07 PM
Peltz Stuart WalterChief Executive OfficerMay 05Option Exercise10.85109,9281,192,719166,013May 07 03:44 PM
Peltz Stuart WalterChief Executive OfficerMay 05Sale50.34109,9285,533,59256,085May 07 03:44 PM
Jacobson Allan StevenDirectorApr 20Option Exercise10.8517,900194,21526,398Apr 21 04:13 PM
Jacobson Allan StevenDirectorApr 20Sale51.0417,900913,5588,498Apr 21 04:13 PM
Jacobson Allan StevenDirectorApr 17Option Exercise10.852,10022,78510,598Apr 21 04:13 PM
Utter Christine MarieSVP, Finance & CAOApr 17Option Exercise18.012,14538,63111,449Apr 21 04:15 PM
Utter Christine MarieSVP, Finance & CAOApr 17Sale50.002,145107,2509,304Apr 21 04:15 PM
Jacobson Allan StevenDirectorApr 17Sale50.162,100105,3328,498Apr 21 04:13 PM
Utter Christine MarieSVP, Finance & CAOApr 03Option Exercise11.237878,83810,091Apr 07 04:05 PM
Utter Christine MarieSVP, Finance & CAOApr 03Sale44.3178734,8729,304Apr 07 04:05 PM
SCHMERTZLER MICHAELDirectorMar 16Buy32.4810,000324,846100,066Mar 18 05:05 PM
open in yahoo | open in reuters | open in google
affiliate • advertise • contact • privacy • help
Do not sell my personal information
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2021 FINVIZ.com. All Rights Reserved.